EP3431991 - KIT AND METHOD FOR MEASURING PROSTAGLANDIN E-MAJOR URINARY METABOLITE [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 17.06.2022 Database last updated on 31.08.2024 | |
Former | The patent has been granted Status updated on 09.07.2021 | ||
Former | Grant of patent is intended Status updated on 28.02.2021 | ||
Former | Request for examination was made Status updated on 21.12.2018 | ||
Former | The international publication has been made Status updated on 22.09.2017 | Most recent event Tooltip | 14.06.2024 | Lapse of the patent in a contracting state New state(s): TR | published on 17.07.2024 [2024/29] | Applicant(s) | For all designated states Fujirebio Inc. 1-1 Nishishinjuku 2-chome Shinjuku-ku Tokyo 163-0410 / JP | [2019/04] | Inventor(s) | 01 /
KATAGIRI, Noriko c/o Advanced Life Science Institute Inc. 51 Komiya-machi Hachioji-shi Tokyo 192-0031 / JP | 02 /
YAGI, Shintaro c/o Advanced Life Science Institute Inc. 51 Komiya-machi Hachioji-shi Tokyo 192-0031 / JP | [2019/04] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2021/32] |
Former [2019/04] | Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB | Application number, filing date | 17766612.0 | 13.03.2017 | [2019/04] | WO2017JP09963 | Priority number, date | JP20160049961 | 14.03.2016 Original published format: JP 2016049961 | [2019/04] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017159612 | Date: | 21.09.2017 | Language: | JA | [2017/38] | Type: | A1 Application with search report | No.: | EP3431991 | Date: | 23.01.2019 | Language: | EN | [2019/04] | Type: | B1 Patent specification | No.: | EP3431991 | Date: | 11.08.2021 | Language: | EN | [2021/32] | Search report(s) | International search report - published on: | JP | 21.09.2017 | (Supplementary) European search report - dispatched on: | EP | 18.09.2019 | Classification | IPC: | G01N33/53, G01N33/543, G01N33/88 | [2019/04] | CPC: |
G01N33/88 (EP,US);
G01N33/54393 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/04] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | KIT UND VERFAHREN ZUR MESSUNG DES PROSTAGLANDIN-E-HAUPTURINMETABOLITS | [2019/04] | English: | KIT AND METHOD FOR MEASURING PROSTAGLANDIN E-MAJOR URINARY METABOLITE | [2019/04] | French: | TROUSSE ET PROCÉDÉ DE MESURE DE MÉTABOLITE URINAIRE MAJEUR DE PROSTAGLANDINE E | [2019/04] | Entry into regional phase | 20.09.2018 | Translation filed | 27.09.2018 | National basic fee paid | 27.09.2018 | Search fee paid | 27.09.2018 | Designation fee(s) paid | 27.09.2018 | Examination fee paid | Examination procedure | deleted | Date on which the examining division has become responsible | 27.09.2018 | Examination requested [2019/04] | 14.04.2020 | Amendment by applicant (claims and/or description) | 01.03.2021 | Communication of intention to grant the patent | 06.07.2021 | Fee for grant paid | 06.07.2021 | Fee for publishing/printing paid | 06.07.2021 | Receipt of the translation of the claim(s) | Opposition(s) | 12.05.2022 | No opposition filed within time limit [2022/29] | Fees paid | Renewal fee | 30.09.2018 | Renewal fee patent year 03 | 12.03.2020 | Renewal fee patent year 04 | 25.03.2021 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 13.03.2017 | AL | 11.08.2021 | AT | 11.08.2021 | CY | 11.08.2021 | CZ | 11.08.2021 | DK | 11.08.2021 | EE | 11.08.2021 | ES | 11.08.2021 | FI | 11.08.2021 | HR | 11.08.2021 | LT | 11.08.2021 | LV | 11.08.2021 | MC | 11.08.2021 | MK | 11.08.2021 | NL | 11.08.2021 | PL | 11.08.2021 | RO | 11.08.2021 | RS | 11.08.2021 | SE | 11.08.2021 | SI | 11.08.2021 | SK | 11.08.2021 | SM | 11.08.2021 | TR | 11.08.2021 | BG | 11.11.2021 | NO | 11.11.2021 | GR | 12.11.2021 | IS | 11.12.2021 | PT | 13.12.2021 | IE | 13.03.2022 | LU | 13.03.2022 | BE | 31.03.2022 | CH | 31.03.2022 | LI | 31.03.2022 | [2024/29] |
Former [2024/23] | HU | 13.03.2017 | |
AL | 11.08.2021 | ||
AT | 11.08.2021 | ||
CY | 11.08.2021 | ||
CZ | 11.08.2021 | ||
DK | 11.08.2021 | ||
EE | 11.08.2021 | ||
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
MC | 11.08.2021 | ||
MK | 11.08.2021 | ||
NL | 11.08.2021 | ||
PL | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SE | 11.08.2021 | ||
SI | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
GR | 12.11.2021 | ||
IS | 11.12.2021 | ||
PT | 13.12.2021 | ||
IE | 13.03.2022 | ||
LU | 13.03.2022 | ||
BE | 31.03.2022 | ||
CH | 31.03.2022 | ||
LI | 31.03.2022 | ||
Former [2024/20] | HU | 13.03.2017 | |
AL | 11.08.2021 | ||
AT | 11.08.2021 | ||
CY | 11.08.2021 | ||
CZ | 11.08.2021 | ||
DK | 11.08.2021 | ||
EE | 11.08.2021 | ||
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
MC | 11.08.2021 | ||
NL | 11.08.2021 | ||
PL | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SE | 11.08.2021 | ||
SI | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
GR | 12.11.2021 | ||
IS | 11.12.2021 | ||
PT | 13.12.2021 | ||
IE | 13.03.2022 | ||
LU | 13.03.2022 | ||
BE | 31.03.2022 | ||
CH | 31.03.2022 | ||
LI | 31.03.2022 | ||
Former [2024/18] | HU | 13.03.2017 | |
AL | 11.08.2021 | ||
AT | 11.08.2021 | ||
CZ | 11.08.2021 | ||
DK | 11.08.2021 | ||
EE | 11.08.2021 | ||
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
MC | 11.08.2021 | ||
NL | 11.08.2021 | ||
PL | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SE | 11.08.2021 | ||
SI | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
GR | 12.11.2021 | ||
IS | 11.12.2021 | ||
PT | 13.12.2021 | ||
IE | 13.03.2022 | ||
LU | 13.03.2022 | ||
BE | 31.03.2022 | ||
CH | 31.03.2022 | ||
LI | 31.03.2022 | ||
Former [2023/10] | AL | 11.08.2021 | |
AT | 11.08.2021 | ||
CZ | 11.08.2021 | ||
DK | 11.08.2021 | ||
EE | 11.08.2021 | ||
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
MC | 11.08.2021 | ||
NL | 11.08.2021 | ||
PL | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SE | 11.08.2021 | ||
SI | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
GR | 12.11.2021 | ||
IS | 11.12.2021 | ||
PT | 13.12.2021 | ||
IE | 13.03.2022 | ||
LU | 13.03.2022 | ||
BE | 31.03.2022 | ||
CH | 31.03.2022 | ||
LI | 31.03.2022 | ||
Former [2023/09] | AL | 11.08.2021 | |
AT | 11.08.2021 | ||
CZ | 11.08.2021 | ||
DK | 11.08.2021 | ||
EE | 11.08.2021 | ||
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
MC | 11.08.2021 | ||
NL | 11.08.2021 | ||
PL | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SE | 11.08.2021 | ||
SI | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
GR | 12.11.2021 | ||
IS | 11.12.2021 | ||
PT | 13.12.2021 | ||
IE | 13.03.2022 | ||
LU | 13.03.2022 | ||
CH | 31.03.2022 | ||
LI | 31.03.2022 | ||
Former [2023/08] | AL | 11.08.2021 | |
AT | 11.08.2021 | ||
CZ | 11.08.2021 | ||
DK | 11.08.2021 | ||
EE | 11.08.2021 | ||
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
MC | 11.08.2021 | ||
NL | 11.08.2021 | ||
PL | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SE | 11.08.2021 | ||
SI | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
GR | 12.11.2021 | ||
IS | 11.12.2021 | ||
PT | 13.12.2021 | ||
IE | 13.03.2022 | ||
LU | 13.03.2022 | ||
Former [2022/47] | AL | 11.08.2021 | |
AT | 11.08.2021 | ||
CZ | 11.08.2021 | ||
DK | 11.08.2021 | ||
EE | 11.08.2021 | ||
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
MC | 11.08.2021 | ||
NL | 11.08.2021 | ||
PL | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SE | 11.08.2021 | ||
SI | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
GR | 12.11.2021 | ||
IS | 11.12.2021 | ||
PT | 13.12.2021 | ||
Former [2022/36] | AL | 11.08.2021 | |
AT | 11.08.2021 | ||
CZ | 11.08.2021 | ||
DK | 11.08.2021 | ||
EE | 11.08.2021 | ||
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
NL | 11.08.2021 | ||
PL | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SE | 11.08.2021 | ||
SI | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
GR | 12.11.2021 | ||
IS | 11.12.2021 | ||
PT | 13.12.2021 | ||
Former [2022/29] | AL | 11.08.2021 | |
AT | 11.08.2021 | ||
CZ | 11.08.2021 | ||
DK | 11.08.2021 | ||
EE | 11.08.2021 | ||
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
NL | 11.08.2021 | ||
PL | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SE | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
GR | 12.11.2021 | ||
IS | 11.12.2021 | ||
PT | 13.12.2021 | ||
Former [2022/25] | AT | 11.08.2021 | |
CZ | 11.08.2021 | ||
DK | 11.08.2021 | ||
EE | 11.08.2021 | ||
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
NL | 11.08.2021 | ||
PL | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SE | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
GR | 12.11.2021 | ||
IS | 11.12.2021 | ||
PT | 13.12.2021 | ||
Former [2022/24] | AT | 11.08.2021 | |
CZ | 11.08.2021 | ||
DK | 11.08.2021 | ||
EE | 11.08.2021 | ||
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
NL | 11.08.2021 | ||
PL | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SE | 11.08.2021 | ||
SK | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
GR | 12.11.2021 | ||
IS | 11.12.2021 | ||
PT | 13.12.2021 | ||
Former [2022/21] | AT | 11.08.2021 | |
DK | 11.08.2021 | ||
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
NL | 11.08.2021 | ||
PL | 11.08.2021 | ||
RS | 11.08.2021 | ||
SE | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
GR | 12.11.2021 | ||
IS | 11.12.2021 | ||
PT | 13.12.2021 | ||
Former [2022/16] | AT | 11.08.2021 | |
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
NL | 11.08.2021 | ||
PL | 11.08.2021 | ||
RS | 11.08.2021 | ||
SE | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
GR | 12.11.2021 | ||
IS | 11.12.2021 | ||
PT | 13.12.2021 | ||
Former [2022/10] | AT | 11.08.2021 | |
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
PL | 11.08.2021 | ||
RS | 11.08.2021 | ||
SE | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
GR | 12.11.2021 | ||
IS | 11.12.2021 | ||
PT | 13.12.2021 | ||
Former [2022/09] | AT | 11.08.2021 | |
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
LT | 11.08.2021 | ||
RS | 11.08.2021 | ||
SE | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
PT | 13.12.2021 | ||
Former [2022/08] | AT | 11.08.2021 | |
ES | 11.08.2021 | ||
FI | 11.08.2021 | ||
LT | 11.08.2021 | ||
SE | 11.08.2021 | ||
BG | 11.11.2021 | ||
NO | 11.11.2021 | ||
Former [2022/07] | AT | 11.08.2021 | |
LT | 11.08.2021 | ||
NO | 11.11.2021 | Documents cited: | Search | [Y]EP0166583 (ONO PHARMACEUTICAL CO [JP]) [Y] 1-15 * example 2 *; | [Y]EP1870708 (FUJIREBIO KK [JP], et al) [Y] 1-15 * example 1 *; | [Y] - INAGAWA T ET AL, "SIMPLIFIED IMMUNOASSAYS OF PROSTAGLANDIN E MAIN METABOLITE IN HUMAN URINE", ADVANCES IN PROSTAGLANDIN, THROMBOXANE, AND LEUKOTRIENE RESEARCH 5TH INTERNATIONAL PROSTAGLANDIN CONFERENCE; FLORENCE, ITALY, MAY 18-21, 1982,, (19830521), vol. 11, pages 191 - 196, XP009104268 [Y] 1-15 * page 192 - page 193 * | International search | [A]JPS6111664 (ONO PHARMACEUTICAL CO) [A] 1-15* , examples 1, 2 & EP 166583 A2 examples 1, 2 *; | [A]WO2006118004 (FUJIREBIO KK [JP], et al) [A] 1-15 * , example 1 & US 2009/0130775 A1 example 1 & EP 1870708 A1 & CA 2605152 A1 & CN 101133323 A *; | [A] - SATORU ITO et al., "In regard to urinary PGE- MUM : interstitial pneumonia", The Cell, (20131120), vol. 45, no. 12, ISSN 1346-7557, pages 581 - 584, XP009513884 [A] 1-15 |